SRF
RNAC icon

Silver Rock Financial’s Cartesian Therapeutics RNAC Stock Holding History

Silver Rock Financial’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-15,262
Closed -$1.09M – 20
2019
Q4 		$1.09M Hold
15,262
– – 0.41% 16
2019
Q3 		$801K Hold
15,262
– – 0.23% 17
2019
Q2 		$820K Hold
15,262
– – 0.2% 19
2019
Q1 		$1.08M Hold
15,262
– – 0.38% 21
2018
Q4 		$1.21M Sell
15,262
-10,971
-42% -$2.5M 0.77% 22
2018
Q3 		$12.2M Hold
26,233
– – 2.15% 10
2018
Q2 		$10.4M Buy
26,233
+1,397
+6% +$496K 2.29% 18
2018
Q1 		$7.58M Buy
24,836
+2,268
+10% +$646K 1.65% 18
2017
Q4 		$6.64M Hold
22,568
– – 1.72% 13
2017
Q3 		$12.4M Hold
22,568
– – 1.65% 6
2017
Q2 		$13.4M Hold
22,568
– – 3.86% 8
2017
Q1 		$9.68M Buy
22,568
+7,199
+47% +$3.03M 4.56% 11
2016
Q4 		$7.91M Buy
+15,369
New +$8.98M 3.52% 9

Other funds holding RNAC

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Silver Rock Financial's RNAC Position: Q1 2020 in Review

Silver Rock Financial sold out of Cartesian Therapeutics (RNAC) in Q1 2020, closing a stake of 15,262 shares — an estimated $1.09M sold.

Silver Rock Financial first reported a position in RNAC in Q4 2016 and held it in 13 quarters. The position peaked at $13.4M in Q2 2017. 61 funds tracked by Wall St. Rank hold RNAC as of Q1 2020.

  • Silver Rock Financial reported no remaining Cartesian Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Silver Rock Financial sold 15,262 Cartesian Therapeutics shares in Q1 2020, an estimated $1.09M.
  • Silver Rock Financial first reported a position in Cartesian Therapeutics in Q4 2016 and held it in 13 quarters.
  • Silver Rock Financial's Cartesian Therapeutics position peaked at $13.4M in Q2 2017.
  • 61 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2020.

Based on Silver Rock Financial's 13F filing for Q1 2020, filed 15 May 2020.